abrdn Life Sciences Investors (NYSE:HQL) Stock Price Down 2.3% – What’s Next?

abrdn Life Sciences Investors (NYSE:HQL) dropped 2.3% on Tuesday . The company traded as low as $17.05 and last traded at $17.19. Approximately 146,167 shares changed hands during trading, an increase of 46% from the average daily volume of 99,899 shares. The stock had previously closed at $17.60.

abrdn Life Sciences Investors Trading Down 1.5%

The stock has a 50-day simple moving average of $17.39 and a two-hundred day simple moving average of $17.07.

abrdn Life Sciences Investors Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Thursday, May 21st will be given a dividend of $0.56 per share. The ex-dividend date of this dividend is Thursday, May 21st. This represents a $2.24 dividend on an annualized basis and a yield of 13.2%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in HQL. Royal Bank of Canada increased its holdings in shares of abrdn Life Sciences Investors by 53.3% in the 1st quarter. Royal Bank of Canada now owns 73,475 shares of the company’s stock valued at $934,000 after acquiring an additional 25,542 shares during the period. NewEdge Advisors LLC increased its holdings in shares of abrdn Life Sciences Investors by 43.1% in the 1st quarter. NewEdge Advisors LLC now owns 32,500 shares of the company’s stock valued at $412,000 after acquiring an additional 9,785 shares during the period. First Trust Advisors LP increased its holdings in shares of abrdn Life Sciences Investors by 112.2% in the 2nd quarter. First Trust Advisors LP now owns 35,321 shares of the company’s stock valued at $452,000 after acquiring an additional 18,674 shares during the period. Raymond James Financial Inc. increased its holdings in shares of abrdn Life Sciences Investors by 20.3% in the 2nd quarter. Raymond James Financial Inc. now owns 375,960 shares of the company’s stock valued at $4,816,000 after acquiring an additional 63,429 shares during the period. Finally, Clough Capital Partners L P purchased a new position in shares of abrdn Life Sciences Investors in the 2nd quarter valued at $318,000. 32.21% of the stock is currently owned by hedge funds and other institutional investors.

About abrdn Life Sciences Investors

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.